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ABSTRACT

Author: Chen, I-Hsuan. Ph.D.
Institution: Purdue University
Degree Received: May 2018
Title: Proteomics Strategies to Develop Proteins of Post-Translational Modifications in PlasmaDerived Extracellular Vesicles as Disease Markers
Major Professor: Weiguo Andy Tao
Blood tests, which are the most wide spread diagnosis procedure in clinical analysis, apply blood
biomarkers to categorize patients and support treatment decisions. However, existing biomarkers
often lack specificity and are far from comprehensive. Mass spectrometry-based proteomics
allow users to characterize plasma protein in great depth and has become a powerful tool in the
biomarker discovery area. However, because of the extremely high dynamic range of plasma,
being able identify thousands of plasma proteins using methods such as Liquid chromatographytandem mass spectrometry (LC-MS/MS) remains a challenge. Furthermore, recent discoveries of
extracellular vesicles (EVs) have proven that EVs have a high possibility for becoming the
source for biomarker discovery and disease diagnosis. In addition to the protein in EVs, posttranslation modification proteins (PTMs proteins) are also interesting targets because the PTMs
proteins are involved with many cancer-related signaling transductions. This dissertation
proposes proteomics strategies of using PTMs proteins in plasma-derived extracellular vesicles
as breast cancer markers. Initially, Chapter One highlights the potential of using phosphoproteins
in extracellular vesicles as markers for breast cancer. Chapter Two delves into the development
of a pipeline proteomics strategy that utilizes glycoproteins in EVs as breast cancer markers.
Finally, Chapter Three explores the details of different subtypes, which presents the possibility
of leveraging three PTMs including phosphorylation, acetylation and glycosylation to distinguish
three major breast cancer subtypes.
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CHAPTER 1.

PHOSPHOPROTEINS IN EXTRACELLULAR VESICLES

AS CANDIDATE MARKERS FOR BREAST CANCER

1.1. Summary
The state of protein phosphorylation can be a key determinant of cellular physiology such as
early stage cancer, but the development of phosphoproteins in biofluids for disease diagnosis
remains elusive. Here we demonstrate a strategy to isolate and identify phosphoproteins in
extracellular vesicles (EVs) from human plasma as potential markers to differentiate disease from
healthy states. We identified close to 10,000 unique phosphopeptides in EVs isolated from small
volumes of plasma samples. Using label-free quantitative phosphoproteomics, we identified 144
phosphoproteins in plasma EVs that are significantly higher in patients diagnosed with breast
cancer compared with healthy controls. Several biomarkers were validated in individual patients
using paralleled reaction monitoring for targeted quantitation. This study demonstrates that the
development of phosphoproteins in plasma EV as disease biomarkers is highly feasible and may
transform cancer screening and monitoring.

1.2. Introduction
Early diagnosis and monitoring of diseases such as cancers through blood tests has been a
decades long aim of medical diagnostics. Since protein phosphorylation is one of the most
important and widespread molecular regulatory mechanisms that controls almost all aspects of
cellular functions(1, 2), the status of phosphorylation events conceivably provides clues regarding
disease status (3). However, few phosphoproteins have been developed as disease markers. Assays
of phosphoproteins from tissues face tremendous challenges due to the invasive nature of tissue
biopsy and the highly dynamic nature of protein phosphorylation during the typically long and
complex procedure of tissue biopsy. Furthermore, biopsy tissue from tumors is not available for
monitoring patient response over the course of treatment. Development of phosphoproteins as
disease biomarkers from biofluids is even more challenging due to the presence of active
phosphatases in high concentration in blood. With a few high abundant proteins representing over

2
95% of the mass in blood, few phosphorylated proteins in plasma/serum can be identified with
stable and detectable concentration.
The recent discovery of extracellular vesicles (EVs), including microvesicles and exosomes,
and their potentially important cellular functions in tumor biology and metastasis has presented
them as intriguing sources for biomarker discovery and disease diagnosis (4-6). Critical for
immune regulation and intercellular communication, EVs have many differentiating
characteristics of cancer cell-derived cargo, including mutations, active miRNAs, and signaling
molecules with metastatic features (7, 8). The growing body of functional studies have provided
strong evidence that these EV-based disease markers can be identified well before the onset of
symptoms or physiological detection of a tumor, making them a promising candidate for earlystage cancer and other diseases (6, 9). Interestingly, EVs are membrane-encapsulated nano- or
microparticles, which protects their inside contents from external proteases and other enzymes
(10-12). These features make them highly stable in a biofluid for extended periods of time, and
also allow us to potentially develop phosphoproteins in EVs for medical diagnoses. The ability to
detect the genome output – active proteins, in particular phosphoproteins – can provide more direct
real time information about the organism’s physiological functions and disease progression,
particularly in cancers.
We aimed to develop EV phosphoproteins as potential disease markers by focusing on breast
cancer in this study. To this end, we isolated and identified the largest group of EV
phosphoproteins to date from both microvesicles and exosomes, and measured phosphorylation
changes across breast cancer patients and healthy individuals. We subsequently identified multiple
potential candidates and verified several among patients and healthy controls. The EV
phosphoproteomics approach demonstrated here can be applied to other systems and thus establish
a new strategy for biomarker discovery.

1.3. Experimental procedure

1.3.1. Plasma Samples
The Indiana University Institutional Review Board approved the use of human plasma samples.
Blood samples were collected from 6 healthy females and from 18 breast cancer patients that
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obtained through the IU Simon Cancer Center. Plasma samples were collected by standard
protocol, in brief, plasma sample processing was initiated within 30 min of blood draw to an
ethylenediaminetetraacetic acid (EDTA) containing tube. Samples were spun for 30 min at 3500
rpm to remove all cell debris and platelet.

1.3.1. Extracellular vesicles isolation
A total 5.5ml pool plasma samples were collected from both healthy control and breast cancer
patient group for technical replicates phosphoproteomics. Plasma samples were centrifuged at
20,000 xg at 4 oC for 1hr. Pellets were washed with cold PBS and centrifuged again at 20,000 xg
at 4 oC for 1 hr, the pellets were microvesicles. Supernatant of first centrifugation were further
centrifuged at ultra-high speed 100,000 xg at 4 oC for 1hr. Pellets were wash with cold PBS and
centrifuged at 100,000 xg for 1hr again. The pellets from ultra-high speed centrifugation were
exosome.
.

1.3.2. Protein digestion
The digestion was performed with phase transfer surfactant aids (PTS) digestion(13).
Extracellular vesicles were solubilized in lysis buffer containing 12mM sodium deoxycholate
(SDC), 12mM sodium lauroyl sarcosinate (SLS) and phosphatase inhibitor cocktail (SigmaAldrich, St. Louis, MO) in 100mM Tris-HCl, pH8.5. Proteins were reduced and alkylated with
10 mM tris-(2-carboxyethyl)phosphine (TECP) and 40 mM chloroacetamide (CAA) at 95 °C for
5 min. Alkylated proteins were diluted to 5 fold by 50mM triethylammonium bicarbonate (TEAB)
and digested with Lys-C (Wako, Japan) in a 1:100 (w/w) enzyme to protein ratio for 3 hr at 37 °C.
Trypsin was added to a final 1:50 (w/w) enzyme-to-protein ratio for overnight digestion. The
digested peptides were acidified with trifluoroacetic acid (TFA) to final concentration of 0.5%
TFA, and 250ul of Ethyl acetate was added to 250ul digested solution. The mixture was shaken
for 2 min, then centrifuged at 13,200 rpm for 2 min to obtain aqueous and organic phases. The
aqueous phase was collected and desalted using a 100 mg of Seppak C18 column (Waters, Milford,
MA).
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1.3.3. Phosphoproteomics enrichment
The phosphopeptide enrichment was performed according to the reported protocol with some
modifications(14). The in-house constructed IMAC tip was made by capping the end with a 20µm
polypropylene frits disk (Agilent, Wilmington, DE, USA). The tip was packed with 5 mg of Ni2+
NTA silica resin by centrifugation. Prior to sample loading, Ni ions were removed by 100 mM
3+
EDTA solution. Furthermore, the beads were chelating with Fe and equilibrated with loading
buffer (6% (v/v) acetic acid (AA) at pH 2.7). Tryptic peptides were reconstituted in loading buffer
and loaded onto the IMAC tip. After successive washes with 4% (v/v) AA, 25% ACN, and 6%
(v/v) AA, the bound phosphopeptides were eluted with 200 mM NH4H2PO4. The eluted
phosphopeptides were desalted using C-18 StageTips (15).

1.3.4. LC-MS/MS analysis
The phosphopeptides were dissolved in 4 µL of 0.3% formic acid (FA) with 3% ACN and
injected into an Easy-nLC 1000 (Thermo Fisher Scientific). Peptides were separated on a 45 cm
in-house packed column (360 µm OD × 75 µm ID) containing C18 resin (2.2 µm, 100Å, Michrom
Bioresources) with a 30 cm column heater (Analytical Sales and Services) and the temperature
was set at 50 °C. The mobile phase buffer consisted of 0.1% FA in ultra pure water (buffer A) with
an eluting buffer of 0.1% FA in 80% ACN (buffer B) run over either with a linear 45 min or 60
min gradient of 6%-30% buffer B at flow rate of 250 nL/min. The Easy-nLC 1000 was coupled
online with a Velos Pro LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific). The mass
spectrometer was operated in the data dependent mode in which a full scan MS (from m/z 3501500 with the resolution of 30,000 at m/z 400). The 10 most intense ions were subjected to
collision induced dissociation (CID) fragmentation (normalized collision energy (NCE) 30%,
AGC 3e4, max injection time 100 ms).

1.3.5. PRM analysis
Peptide samples were dissolved in 8 µl of 0.1% formic acid and injected 6ul into easy nLC
1200 (Thermo) HPLC system. Eluent was introduced into the mass spectrometer using 10cm
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PicoChip® columns filled with 3uM ReprosilPUR C18 (New Objective, Woburn, MA) operated
at 2.6 kV. The mobile phase buffer consists of 0.1% formic acid in water with an eluting buffer of
0.1% formic acid (Buffer A) in 90% CH3CN (Buffer B). The LC flow rate was 300nl/min. The
gradient was set as 0–30% Buffer B for 30 mins and 30-80% for 10mins. The sample was acquired
on Q Exactive HF (Thermo, Germany). Each sample was analyzed under parallel reaction
monitoring (PRM) with an isolation width of ±0.7 Th. In all experiments, a full mass spectrum at
60,000 resolution relative to m/z 200 (AGC target 3 × 106, 100 ms maximum injection time, m/z
400–1600) was followed by up to 20 PRM scans at 15000 resolution (AGC target 1e5, 50 ms
maximum injection time) as triggered by a unscheduled inclusion list. Higher energy collisional
dissociation (HCD) was used with 30eV normalized collision energy.

1.3.6. Data processing
The raw files were searched directly UniprotKB database version Jan2015 with no redundant
entries using MaxQuant software (version 1.5.4.1)(16) with Andromeda search engine. Initial
precursor mass tolerance was set at 20 p.p.m. and the final tolerance was set at 6 p.p.m., and ITMS
MS/MS tolerance was set at 0.6 Da. Search criteria included a static carbamidomethylation of
cysteines (+57.0214 Da) and variable modifications of (1) oxidation (+15.9949 Da) on methionine
residues, (2) acetylation (+42.011 Da) at N-terminus of protein, and (3) phosphorylation (+79.996
Da) on serine, threonine or tyrosine residues were searched. Search was performed with Trypsin/P
digestion and allowed a maximum of two missed cleavages on the peptides analyzed from the
sequence database. The false discovery rates of proteins, peptides and phosphosites were set at
0.01. The minimum peptide length was six amino acids, and a minimum Andromeda score was set
at 40 for modified peptides. A site localization probability of 0.75 was used as the cut off for
localization of phosphorylation sites. All the peptide spectral matches and MS/MS spectra can be
viewed through MaxQuant viewer. All the localized phosphorylation sites and corresponding
phosphoproteins were submitted to pLogo software (17) and Panther (18) to determine the
phosphorylation motifs and gene ontology, respectively. PRM data were manually curated within
Skyline (version 3.5.0.9319)(19)
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1.3.7. Quantitation and Statistical Rationale
All data were analyzed by using the Perseus software (version 1.5.4.1) (20). For quantification
of both proteomic and phosphoproteomic, the intensities of peptides and phosphopeptides were
extracted through MaxQuant, and the missing values of intensities were replaced by normal
distribution with a downshift of 1.8 standard deviations and a width of 0.3 standard deviations.
The significantly increased phosphosites or proteins in patient samples were identified by the pvalue is significant from a two sample t-test with a permutation-based FDR cut off 0.05 with S0
set on 0.2 for all of data sets. The up-regulated candidate networks were predicted in STRING
version 10.0(21) with the interaction score ≥ 0.4, and the signal networks were visualized using
Cytoscape version 3.4.0(22) with MCODE plugin version 1.4.2(23)

1.4. Result

1.4.1. Identification of 9,643 Unique Phosphopeptides from Plasma Microvesicles and
Exosomes.
The workflow for the isolation of EVs, enrichment of phosphopeptides, and EV
phosphoproteome analyses is illustrated in Fig. 1.1. Microvesicles and exosomes were isolated
from human plasma samples through high-speed and ultra-highspeed centrifugations, respectively,
an approach that has been used in previous studies (13–15). For the initial screening, the plasma
samples were collected and pooled from healthy individuals (n = 6) and from patients diagnosed
with breast cancer (n = 18). After lysis of EVs, proteins were extracted and peptides generated
using trypsin with the aid of phase transfer surfactants for better digestion efficiency and fewer
missed tryptic sites (24). Phosphopeptides were enriched and analyzed by liquid chromatography
tandem mass spectrometry (LC-MS/MS) on a high-speed, high-resolution mass spectrometer. For
each phosphopeptide sample, three technical replicates were performed. Label-free quantification
was performed to determine differential phosphorylation of EV proteins in the plasma of control
and breast cancer patient samples.
The strategy allowed us to identify 9,643 unique phosphopeptides, including 9,225 from
microvesicles and 1,014 from exosomes, representing 1,934 and 479 phosphoproteins in
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microvesicles and exosomes, respectively. On average, close to 7,000 unique EV phosphopeptides
were identified from 1 mL human plasma. As shown in Fig. 1. 2A and Fig. 1.3 A, more than 50%
of exosome phosphopeptides were also identified in microvesicles. Gene ontology analysis of the
phosphoproteins indicated overall similar cellular components and biological functions between
microvesicles and exosomes (Fig. 1.2B and Fig. 1.3B). Although previous large-scale
phosphoproteomics studies revealed that phosphorylation preferentially targets nuclear proteins
(25, 26), a significant portion of the EV phosphoproteomes are distinctively from membranes and
organelles. As expected, proteins annotated as extracellular were significantly overrepresented in
the EV phosphoproteomes. We also found that many EV phosphoproteins are involved in cell–
cell communication, stimulus response, and biogenesis.
The EV phosphoproteome analyses revealed that the distribution of tyrosine, threonine, and
serine phosphorylation (pY, pT and pS) sites is 2.0%, 14.1%, and 83.9%, respectively, for
microvesicle phosphoproteins, which is similar to previously reported site distribution in in vivo
human phosphoproteomes(27) . Interestingly, the distribution of pY in exosomes is an order of
magnitude higher, at 13.7%, which is quite close to the distribution of pT, at 16.1% (Fig. 1.2C).
This apparent discrepancy may reflect the different origins of microvesicles and exosomes.
Microvesicles bud directly from the plasma membrane, whereas exosomes are represented by
endosome-associated proteins, in which proteins such as integrins, hormone receptors, growth
factor receptors, receptor tyrosine kinases, and nonreceptor tyrosine kinases such as Src kinases
are involved. A further motif analysis of pS/T phosphorylation sites revealed overall similar
distribution of general motif to cellular phosphoproteome; for example, the most abundant class
of sites is acidophilic, followed by proline-directed and basophilic (Fig. 1.4 A). However, in the
exosome phosphoproteome, proline-directed phosphorylation constitutes only half of that in
microvesicles, and therefore the motif assay does not show dominant –SP- motif in the exosome
phosphoproteome (Fig. 1.4B).

1.4.2. Cancer-Specific Phosphoproteins in EV.
Label-free quantitation of phosphopeptides with the probability score of phosphorylation site
location over 0.75 was used to identify differential phosphorylation events in patients with breast
cancer from those in healthy individuals. We quantified 3,607 and 461 unique phosphosites and
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identified 156 and 271 phosphosites with significant changes [false discovery rate (FDR) < 0.05
and S0 = 0.2] in microvesicles and exosomes, respectively (Fig. 1.5 A and B). Differential
phosphorylation may be a result of changes in protein expression or changes of a particular site’s
phosphorylation. To distinguish these factors, we also performed label-free quantitation of total
proteomes for both microvesicles and exosomes. We identified 1,996 proteins, 34.4% of which
were also identified with phosphopeptide enrichment. In comparison, 862 proteins were detected
in the phosphorylation data alone, indicating that phosphoproteins are typically of low abundance,
escaping detection via the shotgun proteomics approach. Quantitative analyses of EV proteomes
revealed strikingly similar expression of most proteins in healthy individuals and patients with
cancer (Fig. 1.5A). In comparison, there are a larger number of phosphorylation sites with
significant changes in patient samples, indicating that these phosphorylation differences between
patients with cancer and healthy individuals are not a result of changes in protein expression, and
thus reflect phosphorylation truly specific to patients with cancer. The result also justifies our
approach to developing protein phosphorylation changes, instead of protein expression changes,
as the measurement of disease progression. EV proteomic analyses also revealed that several
protein markers were only identified in microvesicles or exosomes specifically, but at the same
time, there are some protein markers identified in both particles (Fig. 1.6). Western blotting was
carried out with the antibody against CD 31, which is considered an endothelial-derived
microvesicles marker. Although CD 31 was mainly identified in microvesicles, the Western
blotting (WB) experiment and MS data indicated that the current isolation method based on
ultracentrifugation is not entirely specific.
We compared these phosphosites representing 197 unique phosphopeptides that showed
significant increase in patients with breast cancer with all identified unique phosphopeptides in
EV phosphoproteomes (Figs. 1.7 and 1.8). Again, the disparity of relative abundance of pY/pT/pS
and sequence motif in microvesicle and exosomes may be a result of their different origins.
Although phosphopeptides that showed a significant decrease in patients with breast cancer might
be interesting, it is conceivable that these phosphopeptides were not necessarily down-regulated
in EV pools, as EVs from other cell sources could compensate them. Therefore, we focused our
attention on these 197 unique phosphopeptides. Motif analyses of the corresponding phosphosites
found that proline-directed motif (s/tP) decreased significantly, whereas the AB motif increased.
In terms of cellular components, the up-regulated phosphoproteins showed a slightly increased
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share of membrane proteins in MV, whereas there is increase in extracellular proteins in exosome.
We further compared the 197 unique phosphopeptides with a recent comprehensive proteogenomic
study in which breast phosphoproteomics studies were carried out in tissues from 105 patients with
breast cancer (28). We found that a significant portion of these 197 phosphopeptides (>60%) were
also identified by the proteogenomic study (Fig. 1.9A), indicating that EV phosphoproteome is
sensitive and that quantitative analyses of EV phosphoproteomics can identify phosphorylation
events that are disease specific. However, because EVs can be released from diverse types of cells,
the difference could be the result of distinctive immune response or other factors in healthy
individuals and patients with cancer. Nevertheless, the results highlight the advantage of analyzing
EV phosphoproteome through liquid biopsy over tissue biopsy, which is invasive and subject to
variation because of the long procedure.
To better understand the biological roles of differential phosphorylation events, we examined
phosphoproteins specific to patients with cancer, using STRING to identify enriched gene
ontology categories and signaling networks (21). We found that several crucial functions related
to cancer metastasis, membrane reorganization, and intercellular communication were enriched in
cancer-specific EV phosphoproteins (Fig. 1.9B). It is interesting to reveal the central role of SRC
tyrosine kinase with multiple phosphoproteins identified in the study, which is consistent with
previous studies linking an elevated level of activity of SRC to cancer progression by promoting
other signals. Please note that although 16% of phosphoproteins that were up-regulated in patients
with cancer are membrane proteins, and because of relative lack of protein–protein interaction data
with membrane proteins, these membrane proteins were not implicated in the STRING analysis.

1.4.3. Verification of Phosphorylation Specific to Patients with Cancer, Using Parallel Reaction
Monitoring
Because breast cancer is extremely heterogeneous, the chance to identify a single diagnostic
biomarker is likely rare. Instead, the identification of a panel of candidate markers that reflect the
onset and progression of key disease-related signaling events would be feasible to offer better
prognostic value. In an effort to validate the differential phosphorylation of potential markers in
patients with cancer, we applied parallel reaction monitoring (PRM) (29) to quantify individual
EV phosphopeptides in plasma from patients with breast cancer and healthy individuals. Because
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phosphospecific antibodies suitable for construction of ELISA are rarely available, targeted,
quantitative MS approaches such as PRM and MRM (multireaction monitoring) are essential for
initial validation. As a demonstration that PRM can be used to initially verify candidate
phosphoproteins, we selected four phosphoproteins: Ral GTPase activating protein subunit alpha2 (RALGAPA2), cGMP dependent protein kinase1 (PKG1), tight junction protein 2 (TJP2), and
nuclear transcription factor, X box binding protein 1 (NFX1). These four proteins showed
significant phosphorylation up-regulation in patients with cancer, were previously reported as
phosphoproteins, and have been implicated in multiple breast cancer studies (30-33)
Quantitative assays based on PRM were performed with plasma EV samples from 13 patients
with cancer (eight additional patient samples) and seven healthy controls (one additional control).
The relative abundance data of phosphopeptides from four individual proteins are presented as a
linear box-and-whiskers plot (Fig. 1.10). With reference from the figure, RALGAPA2, PKG1, and
TJP2 were observed to be significantly elevated in patients with breast cancer compared with in
control patients. However, the fold difference is noticeably smaller in PRM than label-free
quantification. In particular, NFX1 phosphorylation was only identified in breast cancer samples,
and not in healthy controls, but because of large variation among individual samples, the difference
of NFX1 phosphorylation on the specific site is statistically inconclusive. The data may be the
reflection of dynamic suppression of targeted proteomics such as MRM and PRM. Nevertheless,
large variation among clinical samples underscores current challenges facing biomarker validation.

1.5. Discussion
MS-based proteomic profiling and quantitation holds enormous promise for uncovering
biomarkers. However, successful applications to human diseases remain limited. This is, in large
part, a result of the complexity of biofluids that have an extremely wide dynamic range and are
typically dominated by a few highly abundant proteins. This prevents the development of a
coherent, practical pipeline for systemic screening and validation. Here, we reported in-depth
analyses of phosphoproteomes in plasma EVs and demonstrated the feasibility of developing
phosphoproteins as potential disease biomarkers. Previous studies typically could only identify a
small number of phosphoproteins in plasma, likely as a result of the presence of phosphatases in
the bloodstream, and the level of phosphorylation does not have any clear meaningful connection
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to biological status (34, 35). We presented an MS-based strategy that includes the isolation of EV
particles from human blood, enrichment of EV phosphopeptides, LC-MS/MS analyses, and PRM
quantification for biomarker discovery and quantitative verification. We analyzed samples from
patients with breast cancer, in comparison with healthy controls, to identify candidate breast cancer
biomarkers. These candidates will need to be further evaluated in larger, heterogeneous patient
cohorts of defined breast cancer subtypes in the future. The study highlights our ability to isolate
and identify thousands of phosphopeptides from limited volumes of biobanked human plasma
samples. These findings provide a proof of principle for this strategy to be used to explore existing
resources for a wide range of diseases.
Recently, liquid biopsies (analysis of biofluids such as plasma and urine) have gained much
attention for cancer research and clinical care, as they offer multiple advantages in clinical settings,
including their noninvasive nature, a suitable sample source for longitudinal disease monitoring,
better screenshot of tumor heterogeneity, and so on. Current liquid biopsies primarily focus on the
detection and downstream analysis of circulating tumor cells and circulating tumor DNA. A major
obstacle with the cur-ent methods is the heterogeneity and extreme rarity of the circulating tumor
cells and circulating DNA. EVs offer all the same attractive advantages of a liquid biopsy, but
without the sampling limitation of circulating tumor cells and circulating tumor DNA. At present,
most of the studies on EVs focus on microRNAs and a small portion on EV proteins. The ability
to detect the genome output, and in particular functional proteins such as phosphoproteins, can
arguably provide more useful real-time information about the organism’s physiological functions
and disease progression, such as in the early detection and monitoring of cancers.
Our study clearly indicates that EV phosphoproteomes can be readily captured and analyzed. It is
interesting to know that EV phosphoproteins are stable over a long period of storage time (the
plasma samples from Indiana Biobank were collected more than 5 y ago), which is critical for
applications in clinical tests. However, a thorough investigation on EV phophoproteome stability
might be necessary, as cellular phosphorylation events are extremely dynamic and EVs are
circulating in the blood for long periods of time. EV phosphoproteomes may mainly represent
phosphorylation events that are constitutively active, and therefore insensitive to capturing acute
events. All these questions can be addressed with further studies on well-defined EV samples,
possibly using animal models.
Last, although we present here a feasible strategy to develop phosphoproteins as potential
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disease markers, it relies on the isolation of a good quantity of EVs with high reproducibility. At
this stage, the isolation of microvesicles and exosomes is primarily based on differential highspeed centrifugation, which is not highly specific and is unlikely suitable for clinical settings.
Immunoprecipitation of microvesicles and exosomes may introduce bias and contaminations from
plasma proteins. The development of phosphoproteins as biomarkers is also severely limited by
the availability of phosphospecific antibodies. The inability to develop ELISA or similar
immunobased assays will inevitably depend on alternative validation methods such as MS-based
targeted quantitation and nonantibody-based methods (36, 37). The complexity of biofluids and
the necessity of including EV isolation and phosphopeptide isolation in a sample preparation will
no doubt add extra challenges to the accuracy of MS-based targeted quantitation of heterogeneous
clinical samples.

1.6. Data Access
The raw data, MaxQuant output text files, and supplementary MS quantitation tables for all
proteomic

analyses

have

been

deposited

to

the

ProteomeXchange

Consortium(38)

(http://proteomecentral.proteomexchange.org) with the data set identifier PXD005214.
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Figure 1.1 The workflow of EVs phosphoproteomics
The workflow for EVs phosphoproteomics of plasma samples from patients with breast cancer and
healthy controls. EVs including microvesicles and exosomes were isolated through sequential
high-speed centrifugation, followed by protein extraction, phase transfer surfactant digestion, and
phosphopeptide enrichment for LC-MS analyses.
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Figure 1.2 The identification result of EVs phosphoproteomics
(A) The Venn diagram showing the number of unique phosphopeptides identified in microvesicles and exosomes. (B) Classification of
the identified phosphoproteins based on cellular component and biological function. (C) The distribution of serine/threonine/tyrosine
18

(S/T/Y) phosphopeptides in microvesicles and exosomes.
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Figure 1.3 The identification comparison between microvesicles and exosomes.
(A) The bar chart showing the number of unique phosphopeptides identified in microvesicles and exosomes. The values indicated the
mean identification numbers of technical replicates, the error bar shows the SD between replicates. (B) Classification of the identified
phosphoproteins based on cellular component and biological function. The values indicated the mean of technical replicates; the error
bar shows the SD between replicates.
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Figure 1.4 The classification and motif analysis of phosphosites.
(A) Classification of phosphosites based on kinase specificities (P, proline-directed; A, acidophilic; B, basophilic; others). (B) The
summary of motifs were extracted from the sequence windows of identified probability >0.75 phosphorylation sites by pLogo.
20
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Figure 1.5 The Quantitation result of EVs phosphoproteomics between breast cancer and healthy control
(A) The volcano plots representing the quantitative analyses of the phosphoproteomes (Left) and proteomes (Right) of microvesicles
and exosomes in patients with breast cancer vs. in healthy controls. Significant changes in proteins and phosphosites in breast cancer
that were identified through a permutation-based FDR t test (FDR = 0.05; S0 = 0.2), based on three technical replicates. The
significant up-regulated proteins and phosphosites are colored in red, and down-regulated are colored in black. (B) The numbers of
identified phosphopeptides (class 1), quantified phosphosites (class 2), and significantly changed phosphosites (class 3) in label-free
quantification. See supplementary figures and Dataset S1 for more detailed information. (C) The Venn diagram showing the protein
21

overlap between phosphoproteomes and proteomes in microvesicles and exosome.
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Figure 1.6 Examination of EVs isolation from plasma.
(A) The Venn diagram showing the common EVs markers present in MVs and exosome fractions through proteomic analyses. (B)
Western blotting (WB) and MS data showing the purity of EV isolation. Two EV fractions were collected and analyzed by WB using
antibody against CD 31, which is considered an endothelial-derived microvesicles marker. A total of 36 µg protein was used in MV
fraction, and considering exosomes may possibly contain some plasma proteins, around 2.5-fold of protein amount of exosome
fraction was used. MS data were extracted from two EV fractions, and the bar chart showed the intensity mean value with error bar of
control and patient replicates.
22
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Figure 1.7 Comparison of MV phosphopeptides that showed an increase in patients with cancer.
(A) Comparison of cellular components of MV phosphopeptides that showed an increase in patients with cancer, with those of total
phosphopeptides identified in MV. (B–D) Motif and the distribution of S/T/Y phosphopeptides that showed increase in patients with
cancer in microvesicles.
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Figure 1.8 Comparison of exosome phosphopeptides that showed an increase in patients with cancer.
(A) Comparison of cellular components of exosome phosphopeptides that showed increase in patients with cancer with those of total
phospho- peptides identified in exosome. (B–D) Motif and the distribution of S/T/Y phosphopeptides that showed increase in patients
with cancer in exosomes.
24
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Figure 1.9 Networking analysis of up-regulated phosphoproteins
(A) The hierarchical clustering analysis of up-regulated phosphopeptides conveys the overlap between EVs in this study and breast
cancer tissues by Mertins et al. (20). The top bars show the clustering of different samples, and gray represents the tumor samples
analyzed by Mertins et al., whereas blue bars are replicates of MV analysis and cobalt green are exosome analyses in this study. The
fold change is shown in log 2 value. (B) The STRING network analysis of up-regulated phosphoproteins in EVs.
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Figure 1.10 Four potential markers were validated in 13 patients with breast cancer and seven healthy individuals, using PRM.
Three potential markers, RALGAPA2, PRKG1, and TJP2, show significant difference (P < 0.05) in patients with breast cancer compared
26

with healthy control
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CHAPTER 2

A PIPELINE FOR DISCOVERY AND VERIFICATION

OF GLYCOPROTEINS FROM PLASMA-DERIVED
EXTRACELLULAR VESICLES AS BREAST CANCER BIOMARKER

2.1. Summary
Glycoproteins comprise more than half of current FDA-approved protein cancer markers but
the development of new glycoproteins as disease biomarkers has been stagnant. Here we present
a pipeline to develop glycoproteins from extracellular vesicles (EVs) through integrating A
pipeline for discovery and verification of glycoproteins from plasma-derived extracellular vesicles
as breast cancer biomarkers quantitative glycoproteomics with a novel reverse phase glycoprotein
array, and then apply it to identify novel biomarkers for breast cancer. EV glycoproteomics show
promise in circumventing the problems plaguing current serum glycoproteomics and allowed us
to identify hundreds of glycoproteins that have not been identified in serum. We identified 1,453
unique glycopeptides representing 556 glycoproteins in EVs, among which 20 were verified
significantly higher in individual breast cancer patients. We further applied a novel glyco-specific
reverse phase protein array to quantify a subset of the candidates. Together, this study
demonstrates the great potential of this integrated pipeline for biomarker discovery.

2.2. Introduction
The emerging liquid biopsy underscores our unyielding goal of achieving non-invasive disease
diagnosis through blood tests(1). With most proteins present in the blood being glycoproteins and
aberrant glycosylation occurring in many diseases (2), it is not surprising that most common FDA
approved clinically utilized biomarkers for cancer diagnosis and monitoring of malignant
progression are glycoproteins. Examples are prostate-specific antigen (PSA) for prostate cancer,
and carcinoembryonic antigen CEA for colon cancer (3). However, plasma or serum proteomes
contain a dynamic range of 12 orders of magnitude in protein concentration, even a 95% reduction
of major components such as human serum albumin still leaves a dynamic range of 12 orders of
magnitude in concentrations in the sample. As a result, analyzing glycoproteins in blood-derived
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plasma or serum to search for new biomarkers continues to face major challenges in terms of
analytical sensitivity and depth (4, 5). With increasing evidence about their important roles in cellcell communication and relevance in the transmission of pathogenic and signaling molecules in
diseases, extracellular vesicles (EVs) have been exploited as attractive sources for biomarker
discovery and disease diagnosis (6-8). Currently, most studies on EVs focus on mRNA and
miRNA transfer, the role of proteins in EVs, in particular their post-translational modifications
(PTMs) has been rarely exploited (9, 10). PTMs increase the functional diversity of the proteome
and influence almost all aspects of cell biology and pathogenesis. Thus, many PTMs are routinely
tracked as disease markers and used as molecular targets for developing target-specific therapies,
such as the glycoproteins mentioned above. Given that the extracellular vesicles are membraneencapsulated packages, EVs are believed to carry a large assortment of resident cell-surface
glycoproteins (11). In theory, the glycoproteome of EVs should reflect their cellular origins and
functions. A recent study has verified that the altered N-glycoproteome of urinary extracellular
vesicles is associated with prostate cancer (12). Importantly, analyzing the glycoproteome in EVs
instead of plasma or serum could eliminate the interference from highly abundant plasma
components to a large extent, thus providing a wide dynamic range of detection and enabling the
discovery of low-level glycoproteins at high sensitivity (as low as ng/mL) (13). We present here
an integrated pipeline that profiles glycoproteins from EVs through quantitative glycoproteomics
using pooled and individual samples and then validated several targets using a novel reverse phase
glycoprotein array, termed polymer-based reverse phase glycoprotein array (polyGPA) (14). Since
there are few glycosylation-specific antibodies available, verifying glycoproteins as biomarkers in
clinical settings has remained a huge challenge. Although mass spectrometry (MS) has been the
driving force in profiling glycans and glycoproteomes for biomarker research (15, 16), it is often
necessary to enrich either glycoproteins or glycopeptides (17, 18) prior to MS analyses. With its
typical requirements of fair amount of sample, multiple steps for sample preparation, and the
commitment of a high performance instrument, MS-based glycoproteomics is typically used for
in-depth profiling of glycoproteins during the discovery stage. With this pipeline, we identified
1,453 EV N-glycopeptides representing 556 N-glycoproteins, among which 20 EV glycoproteins
showed significant elevation on 21 unique glycosylation sites in breast cancer patient samples. We
applied polyGPA to further validate 5 glycoproteins with samples from another cohort of patient
and healthy individuals. We demonstrate here the universal performance of this pipeline and its
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value in discovering and validating glycoproteins in EVs as novel disease marker.

2.3. Experiment design
2.3.1. Plasma sample
The Indiana University Institutional Review Board approved the use of human plasma
samples. In the global glycoproteomics experiment, blood samples were collected from 6 healthy
females and from 18 breast cancer patients that obtained through the IU Simon Cancer Center. In
the individual verification and PolyGPA validation experiment, blood sample from another 15
healthy controls and 41 breast cancer patients were collected and obtained through Susan G.
Komen Tissue Bank and IU Simon Cancer Center. Plasma samples were collected by standard
protocol, in brief, plasma sample processing was initiated within 30 min of blood draw to an
ethylenediaminetetraacetic acid (EDTA) containing tube. Samples were spun for 30 min at 3500
rpm to remove all cell debris and platelets.
2.3.2. Extracellular Vesicles Isolation
The EVs isolation and digestion were performed according to the reported protocol (10). A
total of 5.5 ml pooled plasma samples were collected from both healthy individuals and patients
diagnosed with breast cancer for the global glycoproteomics experiment as technical replicates.
For the individual verification and polyGPA validation experiments, 0.8ml of plasma was used.
Plasma samples were centrifuged at 20,000 xg at 4 oC for 1hr. Pellets were washed with cold PBS
and centrifuged again at 20,000 xg at 4 oC for 1 hr, the pellets were microvesicles. Supernatant of
the first centrifugation was further centrifuged at 100,000 xg at 4 oC for 1hr. Pellets were washed
with cold PBS and centrifuged at 100,000 xg for 1hr again. The pellets from ultra-high speed
centrifugations were exosome.
2.3.3. Protein Digestion
The digestion was performed with phase transfer surfactant aided (PTS) digestion (19).
Extracellular vesicles were solubilized in lysis buffer containing 12mM sodium deoxycholate
(SDC), 12mM sodium lauroyl sarcosinate (SLS) and phosphatase inhibitor cocktail (Sigma-
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Aldrich, St. Louis, MO) in 100mM Tris-HCl, pH8.5. Proteins were reduced and alkylated with 10
mM tris-(2-carboxyethyl)phosphine (TCEP) and 40 mM chloroacetamide (CAA) at 95 °C for 5
min. Alkylated proteins were diluted to 5 fold by 50mM triethylammonium bicarbonate (TEAB)
and digested with Lys-C (Wako, Japan) in a 1:100 (w/w) enzyme-to-protein ratio for 3 hr at 37
°C. Trypsin was added to a final 1:50 (w/w) enzyme-to-protein ratio for overnight digestion. The
digested peptides were acidified with trifluoroacetic acid (TFA) to final concentration of 0.5%
TFA, and 250ul of Ethyl acetate was added to 250ul digested solution. The mixture was shaken
for 2 min, then centrifuged at 13,200 rpm for 2 min to obtain aqueous and organic phases. The
aqueous phase was collected and desalted using a 100 mg of Sep-pak C18 column (Waters,
Milford, MA).

2.3.4. Glycoproteomics Enrichment
The glycopeptide enrichment was performed according to the reported protocol (14). Desalted
peptides were oxidized with 10 mM sodium periodate in 50% ACN, 0.1% TFA at room
temperature with shaking in the dark for 30 minutes. Excess sodium periodate was quenched by
using 50 mM sodium sulfite for 15 minutes at room temperature with shaking in the dark. The
samples were mixed with 50 µL/100 µL hydrazide magnetic beads for individual and pooled
samples respectively, and incubated with vigorous shaking at room temperature overnight for the
coupling reaction. Magnetic beads were washed sequentially with 400 µL/800 µL of 50% ACN,
0.1% TFA and 1.5 M NaCl for individual and pooled samples respectively, three times per solution
for 1 minute per wash for the removal of non-coupled peptides. Beads were rinsed once with 100
µL/200 µL of 1x GlycoBuffer 2 (NEB) for individual and pooled samples respectively, and
incubated with 3 µL/4 µL of PNGase F (NEB) in 100 µL/200 µL for individual and pooled samples
respectively. N-glycans were cleaved by PNGase F. After desalting, the released former Nglycopeptides were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

2.3.5. LC-MS/MS Analysis
The glycopeptides were dissolved in 4 µL of 0.3% formic acid (FA) with 3% ACN and injected
into an Easy-nLC 1000 (Thermo Fisher Scientific). Peptides were separated on a 45 cm in-house
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packed column (360 µm OD × 75 µm ID) containing C18 resin (2.2 µm, 100Å, Michrom
Bioresources) with a 30 cm column heater (Analytical Sales and Services) set to 50 °C. The mobile
phase buffer consisted of 0.1% FA in ultra-pure water (buffer A) with an eluting buffer of 0.1%
FA in 80% ACN (buffer B) run over either with a 45 min or 60 min linear gradient of 6%-30%
buffer B at flow rate of 250 nL/min. The Easy-nLC 1000 was coupled online with a Velos Pro
LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific). The mass spectrometer was operated
in the data-dependent mode in where The 10 most intense ions were subjected to collision-induced
dissociation (CID) fragmentation (normalized collision energy (NCE) 30%, AGC 3e4, max
injection time 100 ms) for each full MS scan (from m/z 350-1500 with a resolution of 30,000 at
m/z 400).

2.3.6. Data Processing
The raw files were searched directly UniprotKB database version Jan2015 with no redundant
entries using MaxQuant software (version 1.5.6.1) (20) with the Andromeda search engine. Initial
precursor mass tolerance was set to 20 p.p.m. and the final tolerance was set to 6 p.p.m., and ITMS
MS/MS tolerance was set at 0.6 Da. Search criteria included a static carbamidomethylation of
cysteines (+57.0214 Da) and variable modifications of (1) oxidation (+15.9949 Da) on methionine
residues, (2) acetylation (+42.011 Da) at N-terminus of protein, and (3) deamidation (+0.984Da)
on asparagine residues were searched. Search was performed with Trypsin/P digestion and allowed
a maximum of two missed cleavages on the peptides analyzed from the sequence database. The
false discovery rates of proteins, peptides and phosphosites were set at 0.01. The minimum peptide
length was six amino acids, and a minimum Andromeda score was set at 40 for modified peptides.
The glycosylation sites were selected based on the matching to the N-X-S/T (X not Pro) motif. A
site localization probability of 0.75 was used as the cut-off for localization of glycosylation sites.
All the peptide spectral matches and MS/MS spectra can be viewed through MaxQuant viewer.

2.3.7. Quantitative Data Analysis
All data was analyzed using the Perseus software (version 1.5.4.1) (21). For quantification of
both proteomic and glycoproteomic datasets, the intensities of peptides and glycosites were
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derived from MaxQuant, and the missing values of intensities were replaced by normal distribution
with a downshift of 1.8 standard deviations and a width of 0.3 standard deviations. The
significantly increased glycosites or proteins in patient samples were identified by their p-value
from a two sample t-test with a permutation-based FDR cut-off 0.05 with S0 set on 0.2 for all of
data sets. In the individual glycoproteomics data, the intensities were first normalized by
subtracting the median of total intensity, missing values were imputed by normal distribution of
each individual samples with a downshift of 1.8 standard deviations and a width of 0.3 standard
deviations. The imputed data set was further normalized by z-score within each dataset, and the pvalue was calculated by two sample t-test.

2.3.8. Periodate oxidation of plasma EVs
Human plasma microvesicle pellets from healthy and breast cancer-diagnosed individuals
were resuspended with 30 µL of 2% SDS in 100 mM sodium acetate, pH 5.5. Solution was heated
for 10 minutes at 95 °C to lyse microparticles. Protein concentration was measured by the
bicinchoninic acid (BCA) assay. The proteins were then oxidized by 10 mM sodium periodate
with shaking in the dark at room temperature for 30 minutes. The excess sodium periodate was
quenched by 50 mM sodium sulfite with shaking in the dark for 15 min. The oxidized sample was
then denatured in 2% SDS and 2% 2-mercaptoethanol with boiling for 5 minutes.

2.3.9. PolyGPA
The synthesis of PolyGPA reagent was performed according to reported protocol (14).
Nitrocellulose membranes were incubated with the diluted polyGPA reagent overnight at 4 °C.
The coated membranes were air-dried. Prepared oxidized samples were printed on each membrane
using a microarray printing pin (Arrayit® SMP15B). The membrane was washed with 4% SDS in
TBST for three times and then TBST once, 5 min per wash, and then blocked with 3% BSA in
TBST and probed with a primary protein antibody. Membranes were washed three times with
TBST, 5 minutes per wash, and incubated with the corresponding secondary antibody linked with
HRP for tyramide-based signal amplification. Then, membranes were incubated with 5 µM
biotinyl tyramide in 0.003% H2O2 in 100 mM borate buffer (pH 8.5) for 10 min in the dark. The
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membranes were washed with TBST 3 times, 5 minutes per wash, and then probed with IRDye®
680RD Streptavidin (LI-COR Biosciences). Membranes were washed 3 times with TBST, 5
minutes per wash and 2 times with DI water. Finally, membranes were scanned using an infrared
imaging system (LI-COR Odyssey®) and the fluorescent signals were recorded and quantified
using Image Studio (LI-COR Biosciences). After quantification, data was exported to R 3.4 for
further statistical analysis, in brief the mean Intensity signals where used to perform a Mann–
Whitney U test to compare the Intensities among the control and patient groups.

2.3.10. Dynamic Light Scattering (DLS)
To characterize the size of EVs, DLS were performed by Malvern Nano-S Zetasizer, at Birck
Nanotechnology Center, Purdue University. Due to the Brownian motion of the particle, the
velocity distribution of nano-particle movement can be analyzed by measuring dynamic
fluctuations of light scattering intensity, which yields the particle diameter by Stokes-Einstein
equation indirectly. After 20 K and 100 K centrifugation, MVs and exosomes were isolated. The
EVs pellets were resuspended in 1000ul and 100ul of PBS buffer, respectively. The background
was set as PBS buffer with the refraction index at 1.33 equilibrated at 25 .

2.4. Result
2.4.1. Identification of 1,453 unique N-glycopeptides from plasma EV

An overview of EV glycoprotein biomarker pipeline and its application to the identification of
potential breast cancer biomarkers is illustrated in Fig.2.1. Global quantitative Nglycoproteomics
was carried out with EVs, including microvesicles (MVs) and exosomes, using both pooled and
individual samples from healthy and patient plasma, to generate a candidate biomarker list. Plasma
samples were collected and pooled from healthy individuals (n= 18) and from patients diagnosed
with breast cancer (n=18). MVs and exosomes were isolated from human plasma through high
speed and ultra-high speed centrifugation, respectively. The isolation specificity was evaluated
using dynamic light scattering (DLS) (Fig.2.2A), immunoassay with an EV marker antibody, and
mass spectrometry (MS) (Figure 2.3). The DLS data indicated that most MVs isolated after 20K
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centrifugation are in the range of 100-1000 nm while exosomes isolated by 100K centrifugation
are in the range of 30-100nm. MS analyses identified several protein markers only in microvesicles
or exosomes, but at the same time a few surface markers were identified in both microvesicles and
exosomes, indicating either current markers for exosome and microvesicles are not totally specific
or the differential centrifugation method is not entirely specific. Western Blotting was carried out
with the antibody against CD31 which is considered an endothelial derived microvesicles marker
and the data showed that CD31 was indeed mainly identified in microvesicles. After isolation,
EVs were lysed, proteins were extracted and enzymatically digested with LysC and trypsin,
followed by the hydrazide chemistry to enrich pre-oxidized glycopeptides. N-glycopeptides were
recovered using PNGase F and analyzed by nanoflow LC-MS/MS. For each glycopeptide sample,
three technical replicates were performed and label free quantitation was performed to measure
glycopeptides in EV samples in the plasma of control and breast cancer patient samples.
We identified 1,453 unique glycopeptides, including 1,337 from microvesicles and 447 from
exosomes, representing 526 and 164 glycoproteins in MV and exosomes, respectively (Fig.2.2B).
Gene ontology analysis of the glycoproteins indicated a significant portion of the identified
glycoproteins are from membrane, extracellular region, and organelles (Fig.2.2C). Overall, similar
cellular components were observed for MV and exosomes. There is also significant overlap of
identified glycopeptides and glycoproteins in MV and exosomes. With only 30 glycoproteins
being unique in exosomes, we reasoned that it is not critical to differentiate glycoproteins in MV
from those in exosomes for disease biomarker discovery and therefore all following data collected
in MVs and exosomes in this study were combined and analyzed as EV N-glycoproteomes.
The current data reported here represents one of the largest N-glycoproteomic datasets using serum
or plasma as the source. For direct comparison, we carried out a conventional N-glycoproteomic
study using the breast cancer plasma samples. The conventional workflow with plasma samples
resulted in a larger portion of high abundant plasma glycoproteins while EV glycoproteomics
identified more glycoproteins in low abundance (Fig.2.4A). We further examined the identified
EV N-glycoproteins against previous reported serum/plasma glycoproteins. Strikingly, about one
quarter (126) of glycoproteins have not been previously reported as serum/plasma glycoproteins
(Fig. 2.4B). The data supports our hypothesis that EVs are an ideal source to identify novel
glycoproteins as potential disease biomarkers.
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2.4.2. Cancer-specific glycoproteins in EV
Label-free quantitation of glycopeptides was performed to identify a list of glycoproteins
changing in breast cancer. We quantified 1106 unique glycosites and identified 77 glycopeptides
with a significant difference in abundance in breast cancer patients versus healthy controls
(Fig.2.5A). The difference in glycopeptides may be a result of changes in protein expression or
changes of glycosylation on specific sites. To distinguish these factors, we also performed labelfree quantitation of total EV proteomes. We identified 1,996 proteins, only 177 of which were
also identified with glycopeptide enrichment. Therefore, analyses of the glycoproteme
contributes to a deeper coverage of the EV proteome. Quantitative analyses of EV proteomes
revealed strikingly similar expression of most proteins in healthy individuals and cancer patients
(Fig.2.5B). In comparison, there are a larger number of glycopeptides with significant changes in
patient samples, indicating that these glycosylation differences between cancer patients and
healthy individuals are not due to changes in protein expression, and thus reflect true cancer
patient-specific glycosylation. We then carried out label-free quantitative EV glycoproteomics
with individual plasma samples from 18 patients with breast cancer and 10 healthy controls.
Glycoproteins with significantly increased glycosylation in patient samples were identified by
the p-value from a two sample t-test with a permutation-based FDR cut-off 0.05 with S0 set on
0.2. The imputed data set was further normalized by z-score for the heatmap analysis and
together, we identified a total of 20 glycoproteins specific in patients with 21 unique
glycosylation sites (P-value <0.05) (Fig.2.5C).

2.4.3. Verification of specific glycoprotein changes in cancer patients via polyGPA
We reason that breast cancer is extremely heterogeneous and instead of identifying a single
diagnostic biomarker, the identification of a panel of candidate glycoproteins that reflect the onset
and progression of breast cancer would offer better prognostic value. Validation of biomarkers has
been carried out using antibody-based Sandwich assays such as ELISA or targeted quantitative
MS methods like selected reaction monitoring (SRM) and multiple reaction monitoring (MRM).
However, there are virtually no existing antibodies specific for glycosylated proteins. On the other
hand, the development of SRM/MRM assays requires a great deal of efforts including the high
cost of synthetic stable isotope labeled peptides, in particular here formerly N-glycosylated
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peptides. Thus, in an effort to verify increased glycoproteins in specific cancer patients, we applied
a novel reverse phase protein array specific for glycoproteins to quantify individual EV
glycoproteins in plasma from breast cancer patients and healthy individuals. We have recently
developed a three-dimensionally functionalized reverse phase protein array, polyGPA, to validate
glycoproteins in high throughput. PolyGPA uses hydroxyamino dendrimer-modified
nitrocellulose to covalently capture pre-oxidized glycans on glycoproteins, followed by onmembrane detection using the same validated antibodies as in typical reverse phase protein arrays.
Although no glycosylation specific antibody or lectin is used, any change in polyGPA signal is
attributed to the change in overall glycosylation of targeted glycoprotein. In addition, we
demonstrated that polyGPA’s sensitivity is much higher than RPPA (over 10-fold signal increase)
for the same protein concentration, likely due to improved orientation of glycoproteins during their
glycan binding to the polyGPA membrane, exposing more epitopes for increased overall signal.
We prioritized the glycoproteins for further verification by polyGPA through their biological
relevance to cancer in previous studies and availability of their antibodies which are validated by
Human Protein Atlas (HPA) project for high specificity. Among the glycoproteins that show
significant increase in breast cancer patients (Fig.2.5C), some are known plasma/serum
glycoproteins while others have never been detected from blood. Interestingly, 70% of the
glycoproteins on the list have previously been identified from cancer tissues (Figure 2.7)(22),
highlighting the important feature of this biomarker strategy which did not require an invasive
biopsy but rather used EVs as the source to identify biomarkers previously reported in cancer
tissue studies. We selected 6 EV glycoproteins, a membrane protein Lymphocyte antigen 6
complex locus protein G6f (LY6G6F), a multimeric plasma glycoprotein von willebrand factor
(VWF), CD147/basigin (BSG), Complement C1q subcomponent subunit A (C1QA),
Angiopoietin-1 (ANGPT1/Ang1), and Cadherin-6 (CDH6) for further verification with another
cohort of plasma samples from 28 breast cancer patients and 10 healthy controls. EVs were isolated
from plasma samples, lysed, pre-oxidized and each individual sample was printed onto the
polyGPA membranes and unfunctionalized membranes as in regular RPPA. Specific protein
antibodies were then used to detect and quantify endogenous LY6G6F, VWF, BSG, C1QA,
ANGPT1, and CDH6 signals in individual samples. As shown in Figure 2.6, measurements by
polyGPA showed much better sensitivity because of significantly reduced sample complexity after
the enrichment of glycoproteins on the functionalized membrane and better orientation of
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glycoproteins for epitope detection by the antibodies. This enhanced sensitivity proved to be
critical for the detection of proteins with much lower abundances, such as BSG, C1QA, ANGPT1,
and CDH6, and their protein signals were barely detectable in RPPA (Figure 2.6c-f). Five out of
six glycoproteins, except CDH6, showed statistically significant specificity (p<0.05) for breast
cancer. The quantitative measurements with polyGPA and RPPA also allowed us to identify
whether glycosylation elevation is due to changes in protein expression or changes in
glycosylation. Significant elevation in both polyGPA and RPPA for LY6G6F. The increase in
breast cancer patients was clearly observed in polyGPA for VWF, but the difference is small in
RPPA (the distinction is largely due to one outlier; Figure 5b), indicating that that the glycosylation
elevation in cancer patients is likely due to changes in patient-specific glycosylation. As stated
above, due to low abundance, BSG, C1QA, ANGPT1 and CDH6 could only be quantified by
polyGPA, further highlighting its uniqueness and high sensitivity for clinical samples.
2.5. Discussion
Glycosylated proteins are one important class of proteins that play important roles in a wide
range of cellular functions and have also been utilized for disease diagnosis. Development of new
glycoproteins as potential biomarkers, however, has struggled due to the lack of good tools. The
purpose of this study was to continue our efforts to develop novel glycoproteins as potential disease
biomarkers by proposing new strategies and new analytical platforms. We tested the hypothesis
that, to overcome the great complexity of protein glycosylation at the presence of thousands of
proteins in serum in which a number of highly abundant serum proteins are glycoproteins,
glycoproteins from EVs are valuable sources for biomarker discovery and disease diagnosis. Here,
we reported in-depth analyses of N-glycoproteomes in plasma EVs and demonstrated the
feasibility of developing glycoproteins as potential breast cancer biomarkers. With multiple high
abundant glycoproteins that prevent us from exploring disease-relevant, typically low abundant
glycoproteins in blood, this method relies on glycoproteins EVs to efficiently identify many
glycoproteins that are difficult to detect using existing methods.
This study also addresses a major issue in the development of glycoproteins for biomarker
discovery, i.e., how to validate specific glycoproteins in high throughput. Without glycospecific
antibodies, SRM/MRM appeared as the only choice but it requires considerable efforts including
the synthesis of isotopic labeled formerly glycosylated peptides. Instead, we introduced polyGPA
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as an alternative and novel high throughput method for simple, sensitive quantification of
glycoproteins in array format. Using glyco-specific, 3-dimensional functionalized membrane to
capture glycoproteins followed by detection using high quality antibodies, the new platform
allowed us to measure glycoproteins in multiple clinical samples in parallel. Here we developed a
novel biomarker discovery pipeline that focuses on glycoproteins from plasma-derived EVs and
integrates high performance LC-MS/MS for candidate discovery with novel glycoprotein-specific
RPPA for v. We applied the pipeline to identify EV glycoproteins as novel breast cancer
biomarkers. Using data-dependent LC-MS/MS-based EV N-glycoproteomics, we identified 1,453
unique N-glycopeptides in the plasma EVs from breast cancer samples, representing 556
glycoproteins that include not only known plasma proteins spanned several orders of magnitude
of abundance, but also non-plasma proteins that were identified only from tissues previously.
Among them, 20 glycoproteins were quantified with significantly elevated level in breast cancer
patients and we further validate 5 glycoproteins with separate cohort of breast cancer patients and
healthy controls. The 5 validated glycoproteins all have been directly linked to or implicated with
cancer according to previous studies. LY6G6F (G6f) is a type I transmembrane protein and
putative cell-surface receptor encoded by a gene in the MHC. Its phosphorylation has been
previously related to downstream signaling pathways including Ras-MAP kinase pathway (23).
VWF is a multimeric plasma glycoprotein and was previously discovered to be highly enriched in
mesenchymal stem/stromal cells-derived EVs (24). Besides its essential role in hemostasis, there
are growing studies connecting it to cancer (25), such as its modulation on angiogenesis and
apoptosis(26) and in tumor metastasis (27). BSG (CD147 or basigin) is also a transmembrane
glycoprotein that is highly expressed by various cancer cells such as malignant melanoma cells
(28). The full length of BSG was identified in microvesicles shedding from lung carcinoma cells
(29). BSG is strongly related to cancer progression, enhancing cancer proliferation and VEGF
production (30). It was reported that it promotes tumor cell glycosylation through facilitating
lactate transport (28). Complement C1q has recently been discovered to act as tumor-promoting
factor by facilitating adhesion, migration and proliferation of cancer cells as well as angiogenesis
and metastasis (31). Angiopoietin-1 (ANGPT1) has been discovered in multiple human breast
cancer cell lines such as MCF-7 and has been shown to play an important role in tumor
angiogenesis (32). Verification of glycoproteins by polyGPA is a unique element of our pipeline,
providing a simple and relatively high throughput method to prioritize a list of candidates meriting
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further validation with larger, heterogeneous patient cohorts. However, the limitations of polyGPA
for clinical validations need to be noticed. First, like other RPPA, its applications are highly
dependent on the availability of validated, high quality antibodies for any novel candidate. Second,
polyGPA only measures the overall glycosylation in a protein. For a glycoprotein with multiple
glycosylation sites, polyGPA may not be sensitive enough to a glycosylation change on a specific
site. As shown in Fig. 2.8, side-by-side measurement by polyGPA and LC-MS/MS of the same
plasma samples from patients and healthy controls revealed in general attenuated difference on
polyGPA compared to the difference observed by MS. For example, the relative intensity of
ANGPT1 in a breast cancer patient and a healthy individual is almost equal, while MS detected
glycosylation elevation in the patient only on site 122. Since ANGPT1 has at least five Nglycosylation sites, it is conceivable that the glycosylation on the individual site might have been
elevated drastically in patient samples but the overall glycosylation level has minimal change.
2.6.Data Access

The mass spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium (http://proteomecentral.proteomexchange.org) with Project accession number
PDX00757 via the PRIDE partner repository (33).

2.7. Reference

1.

Yong, E. (2014) Cancer biomarkers: Written in blood. Nature 511, 524-526

2.

Pinho, S. S., and Reis, C. A. (2015) Glycosylation in cancer: mechanisms and clinical
implications. Nature reviews. Cancer 15, 540-555

3.

Blixt, O., and Westerlind, U. (2014) Arraying the post-translational glycoproteome (PTG).
Curr Opin Chem Biol 18, 62-69

4.

Hanash, S. M., Pitteri, S. J., and Faca, V. M. (2008) Mining the plasma proteome for cancer
biomarkers. Nature 452, 571-579

5.

Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M., Teupser, D., and Mann, M. (2016)
Plasma Proteome Profiling to Assess Human Health and Disease. Cell Syst 2, 185-195

40
6.

Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., LeBleu,
V. S., Mittendorf, E. A., Weitz, J., Rahbari, N., Reissfelder, C., Pilarsky, C., Fraga, M. F.,
Piwnica-Worms, D., and Kalluri, R. (2015) Glypican-1 identifies cancer exosomes and
detects early pancreatic cancer. Nature 523, 177-182

7.

Gonzales, P. A., Pisitkun, T., Hoffert, J. D., Tchapyjnikov, D., Star, R. A., Kleta, R., Wang,
N. S., and Knepper, M. A. (2009) Large-scale proteomics and phosphoproteomics of urinary
exosomes. Journal of the American Society of Nephrology : JASN 20, 363-379

8.

Boukouris, S., and Mathivanan, S. (2015) Exosomes in bodily fluids are a highly stable
resource of disease biomarkers. Proteomics Clin Appl 9, 358-367

9.

Moreno-Gonzalo, O., Villarroya-Beltri, C., and Sanchez-Madrid, F. (2014) Posttranslational modifications of exosomal proteins. Front Immunol 5, 383

10.

Chen, I. H., Xue, L., Hsu, C. C., Paez, J. S., Pan, L., Andaluz, H., Wendt, M. K., Iliuk, A. B.,
Zhu, J. K., and Tao, W. A. (2017) Phosphoproteins in extracellular vesicles as candidate
markers for breast cancer. Proc Natl Acad Sci U S A 114, 3175-3180

11.

Gerlach, J. Q., and Griffin, M. D. (2016) Getting to know the extracellular vesicle glycome.
Molecular bioSystems 12, 1071-1081

12.

Saraswat, M., Joenvaara, S., Musante, L., Peltoniemi, H., Holthofer, H., and Renkonen, R.
(2015) N-linked (N-) glycoproteomics of urinary exosomes. [Corrected]. Mol Cell
Proteomics 14, 263-276

13.

Sok Hwee Cheow, E., Hwan Sim, K., de Kleijn, D., Neng Lee, C., Sorokin, V., and Sze, S.
K. (2015) Simultaneous Enrichment of Plasma Soluble and Extracellular Vesicular
Glycoproteins Using Prolonged Ultracentrifugation-Electrostatic Repulsion-hydrophilic
Interaction Chromatography (PUC-ERLIC) Approach. Mol Cell Proteomics 14, 1657-1671

14.

Pan, L., Aguilar, H. A., Wang, L., Iliuk, A., and Tao, W. A. (2016) Three-Dimensionally
Functionalized Reverse Phase Glycoprotein Array for Cancer Biomarker Discovery and
Validation. J Am Chem Soc 138, 15311-15314

15.

Ruhaak, L. R., Miyamoto, S., and Lebrilla, C. B. (2013) Developments in the identification
of glycan biomarkers for the detection of cancer. Mol Cell Proteomics 12, 846-855

16.

Zhang, Y., Jiao, J., Yang, P., and Lu, H. (2014) Mass spectrometry-based N-glycoproteomics
for cancer biomarker discovery. Clin Proteomics 11, 18

41
17.

Krishnamoorthy, L., and Mahal, L. K. (2009) Glycomic analysis: an array of technologies.
ACS Chem Biol 4, 715-732

18.

Zhang, H., Li, X. J., Martin, D. B., and Aebersold, R. (2003) Identification and quantification
of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass
spectrometry. Nat Biotechnol 21, 660-666

19.

Masuda, T., Sugiyama, N., Tomita, M., and Ishihama, Y. (2011) Microscale
phosphoproteome analysis of 10,000 cells from human cancer cell lines. Anal Chem 83,
7698-7703

20.

Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates,
individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat
Biotechnol 26, 1367-1372

21.

Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., and
Cox, J. (2016) The Perseus computational platform for comprehensive analysis of
(prote)omics data. Nat Methods 13, 731-740

22.

Hill, J. J., Tremblay, T. L., Fauteux, F., Li, J., Wang, E., Aguilar-Mahecha, A., Basik, M.,
and O'Connor-McCourt, M. (2015) Glycoproteomic comparison of clinical triple-negative
and luminal breast tumors. J Proteome Res 14, 1376-1388

23.

De Vet, E. C., Aguado, B., and Campbell, R. D. (2003) Adaptor signalling proteins Grb2 and
Grb7 are recruited by human G6f, a novel member of the immunoglobulin superfamily
encoded in the MHC. Biochem J 375, 207-213

24.

Eirin, A., Zhu, X. Y., Puranik, A. S., Woollard, J. R., Tang, H., Dasari, S., Lerman, A., van
Wijnen, A. J., and Lerman, L. O. (2016) Comparative proteomic analysis of extracellular
vesicles isolated from porcine adipose tissue-derived mesenchymal stem/stromal cells. Sci
Rep 6, 36120

25.

Franchini, M., Frattini, F., Crestani, S., Bonfanti, C., and Lippi, G. (2013) von Willebrand
factor and cancer: a renewed interest. Thrombosis research 131, 290-292

26.

Terraube, V., Pendu, R., Baruch, D., Gebbink, M. F., Meyer, D., Lenting, P. J., and Denis,
C. V. (2006) Increased metastatic potential of tumor cells in von Willebrand factor-deficient
mice. J Thromb Haemost 4, 519-526

27.

Terraube, V., Marx, I., and Denis, C. V. (2007) Role of von Willebrand factor in tumor
metastasis. Thrombosis research 120 Suppl 2, S64-70

42
28.

Kanekura, T., and Chen, X. (2010) CD147/basigin promotes progression of malignant
melanoma and other cancers. J Dermatol Sci 57, 149-154

29.

Sidhu, S. S., Mengistab, A. T., Tauscher, A. N., LaVail, J., and Basbaum, C. (2004) The
microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene 23, 956963

30.

Ferrara, N. (2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29,
789-791

31.

Bulla, R., Tripodo, C., Rami, D., Ling, G. S., Agostinis, C., Guarnotta, C., Zorzet, S.,
Durigutto, P., Botto, M., and Tedesco, F. (2016) C1q acts in the tumour microenvironment
as a cancer-promoting factor independently of complement activation. Nature
communications 7, 10346

32.

Metheny-Barlow, L. J., and Li, L. Y. (2003) The enigmatic role of angiopoietin-1 in tumor
angiogenesis. Cell Res 13, 309-317

33.

Vizcaino, J. A., Cote, R. G., Csordas, A., Dianes, J. A., Fabregat, A., Foster, J. M., Griss, J.,
Alpi, E., Birim, M., Contell, J., O'Kelly, G., Schoenegger, A., Ovelleiro, D., Perez-Riverol,
Y., Reisinger, F., Rios, D., Wang, R., and Hermjakob, H. (2013) The PRoteomics
IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res 41,
D1063-1069

43

Figure 2.1. Workflow of a pipeline based on plasma EV glycoproteomics for biomarker
discovery.
Microvesicles and exosomes were isolated through sequential high-speed centrifugation,
followed by protein extraction, phase transfer surfactant digestion, and glycopeptide enrichment
using hydrazide chemistry for LC-MS analyses. For global glycoproteomics analyses, 18 cancer
and 6 control samples were pooled to create a preliminary list of increased glycosylated proteins.
Proteomic analyses on 18 individual breast cancer and 10 healthy controls were performed to
further verify the preliminary candidate biomarker list. Finally, Verification of potential
biomarkers was performed using polyGPA.
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Figure 2.2 Characteristic analysis of glycoproteins in plasma-derived EVs.
(A) The size distribution of EVs isolated from two high-speed centrifugations measured by DLS.
Each line corresponds to one acquired result from a single sample; (B) Venn diagram showing
the glycopeptides and glycoproteins identification overlap between microvesicles and exosome.
(C) Classification of the identified glycoproteins in EVs based on their cellular component.
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Figure 2.3 Purity of EVs isolation by high-speed centrifugation.
(A) The Venn diagram showing the common EVs markers present in MVs and exosome fractions through proteomic analyses. (B)
Western blotting (WB) and MS data showing the purity of EV isolation. Two EV fractions were collected and analyzed by WB using
antibody against CD 31, which is considered an endothelial-derived microvesicle marker. A total of 36 µg protein was used in MV
fraction, and considering exosomes may possibly contain some plasma proteins, around 2.5-fold of protein amount of exosome
fraction was used. MS data were extracted from two EV fractions, and the bar chart showed the intensity mean value with error bar of
45

control and patient replicates.
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Figure 2.4 Comparison of glycoproteins in plasma and plasma-derived EVs.
(A) EVs and plasma proteins classification according to their intensities and spectral counts. (B)
Venn diagram showing the overlap of the number of unique glycoproteins identified in EVs in
this study compared to known plasma proteins.
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Figure 2.5Quantitative analysis of EV N-glycoproteomics between breast cancer and healthy
controls.
(A) For global glycoproteomics, 18 breast cancer and 6 healthy controls were pooled to create a
preliminary list of statistically increased glycosylated proteins. Volcano plot representing the
quantitative analysis of the glycoproteomes of microvesicles in breast cancer patients v.s. healthy
controls in left figure and proteomics analysis in (B). See supplementary figure for exosome
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quantitation result. Significant changes in proteins and glycosites in breast cancer were identified
through a permutation-based FDR test (FDR=0.05;S0=0.2) based on three technical replicates.
The significant up-regulated proteins and glycosites are colored in red, and down-regulated are
colored in gray on the left part of the volcano plot; (C) Quantitative glycoproteomics were
performed on individuals to verify the preliminary list found in global glycoproteomics, and pvalue
represents the significance of comparing individual patients and controls. In total, 18 patients and
10 healthy controls were examined in first verification experiment, 5 out of 18 patients and 6 out
of 10 healthy controls were used in both global first individual verification glycoproteomics
experiment (asterisk marked).
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Figure 2.6Verification of selected targets in plasma EVs by PolyGPA.
Quantification of endogenous (a)LY6G6F, (b)VWF, (c)BSG, (d) C1QA, and (e) ANGPT1 (f)
CDH6 in plasma EVs. For each membrane, top three rows were printed with 28 breast cancer
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samples (first two rows with 10 samples and the third row with 8 samples) and the fourth row
with 10 healthy control samples, each with 4 prints per individual sample. For quantitation of
signals in polyGPA, the mean intensity of 4 prints per individual was used and the distribution of
log10 (intensity) is depicted in the left pane.

Figure 2.7 The hierarchical clustering analysis of up-regulated glycoproteins conveys the overlap
between EVs in this study and breast cancer tissues by Hill et. al.
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Figure 2.8 The quantitation results between polyGPA and label-free quantitation by MS of five
glycoprotein candidates.
The EVs from the same patients and controls were collected for both individual N-glycoproteomics
and polyGPA analysis.
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CHAPTER 3

DISCOVERY

GLYCOSYLATION,

AND

OF

PHOSPHORYLATION,

ACETYLATION

PROTEINS

IN

EXTRACELLULAR VESICLES AS BIOMARKERS FOR BREAST
CANCER SUBTYPES

3.1

Summary
Breast cancer is a complex disease that can be majorly classified into four molecular subtypes,

Luminal A/B, Her 2 positive and Triple negative. With a wide variety of pathologic features and
biological behaviors, the diagnosis or prognosis of specific subtypes is critical for applying the
appropriate treatment. Here, we present a novel strategy for developing serial PTM-omics in
plasma-derived EVs as biomarkers to discriminate different subtypes in breast cancer, which is
able to identify 11824, 192, 1259 and 805 of unique pS/T, pY phosphorylation, N-glycosylation
and acetylation peptides respectively in EVs, isolated from plasma samples. Using label-free
quantitative PTMs-omics, several PTMs sites showed significantly higher in certain subtypes, and
PCA further confirms that the expression profile of each PTMs are also different. In addition,
several targets are verified in each subtype by using parallel monitor reaction approach. Together,
this study demonstrates the great potential of this strategy for developing the biomarkers for
different subtypes in breast cancer.

3.2

Introduction
Breast cancer is the most common neoplasm among women in United State. With the

characteristic of highly heterogeneous, it includes a number of biologically distinct substances
with specific pathologic features and biological behaviors(1, 2). There are different risk factors for
different breast cancer subtypes, such as outcome, respond to therapies and histopathological
features(3-5). Therefore, the diagnosis clarification of breast cancer among clinically relevant
subtypes is required. Besides immunochemistry markers, some hallmarks have also been identified
by Weinberg et al.(6) including “sustaining proliferative signaling”, “activating invasion and
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metastasis”, “resisting cell death”, “evading immune destruction” and “reprogramming of energy
metabolism”.
Breast tumors are divided into four basic subgroups according to IHC markers (ER, PR, Her2),
i.e., Luminal A: [ER+][PR+][Her2-], Luminal B: [ER+][PR+][Her2+], Her2 positive (Her2+) :
[ER-][PR-][Her2+] and triple negative (TN): [ER-][PR-][Her2-]. In general, Her2+ and TN have
relatively poorer prognosis than Luminal A and B cancers. For the Luminal A and B subtypes, ER
is known to be the most important biomarker for breast cancer classification and plays crucial roles
in breast carcinogenesis(7). Her 2+ subtypes with Her2 gene amplification and usually tend to
grow faster, but often can be successfully treated with Her2 targeted therapies(8). Triple-negative
breast cancer is hormone receptor and Her 2 negative, and this type of breast cancer is more
common associated with BRCA1 mutation(9).
Notably, both hormonal and growth receptor promote the tumor progression through abnormal
phosphorylation events. Studies indicated that the HER2 activation was consistent with EGFR and
HER3 phosphorylation and downstream signaling activation (10). Moreover, Cuenca-Lopez et. al
found that Androgen receptor is present in TN breast cancer and its expression correlates with
activated receptor tyrosine kinases, such as EGFR, PDGFRb and Erk1/2 (11). Taken together,
phosphorylation is a key PTMs in finding the diagnostic biomarkers and therapeutic targets. Since
many related genes are tyrosine receptor kinase, looking for tyrosine phosphorylation would be
promising to provide us more valuable information.
Another PTMs acetylation has also been associated with promoting breast cancer metastasis,
enhances the promoting role of AlB1 in breast cancer and been implied as another hormone
therapies targets (12). Furthermore, researchers pointed out that enzymes and proteins involved in
lysine acetylation are deregulated in cancer (13), and growing evidences of lysine acetylation links
to cancer related metabolism and signaling pathways (14).
With the fact that most of proteins in plasma are glycosylated, glycoproteins are popular targets
for disease biomarkers, and actually there are more than half of FDA-approved biomarkers for
cancer diagnosis are glycoproteins. In breast cancer, IO et. al had reveal that the differences in
expression of genes related the process of glycosylation exist between breast cancer subtypes.
Another two studies also indicated the aberrant glycosylation in Her 2 positive breast cancer (15,
16). Furthermore, the aberrant glycosylation has been suggested as the biomarker for cancers (17).
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As important features of PTMs proteins in breast cancer are described above, however, very
few of them have been developed as biomarker for disease diagnosis or prognosis. Development
of PTMs proteins as disease biomarkers from biofluids is challenging mainly due to the wide
dynamic range of protein abundance in blood. With a few high abundant proteins representing
over 95% of the mass in blood, few PTMs proteins in plasma/serum can be identified with stable
and detectable concentration.
The discovery of extracellular vesicles in past decade revealed their important roles in cellular
functions in tumorgenesis and metastasis, and it has presented them as intriguing sources for
biomarker discovery and disease diagnosis. The growing evidences have suggested that tumor
secreted EVs have potential on reflecting its cell origin and function, and can be identified before
the physical detection of tumor, making them a promising candidate for early stage cancer. In this
study, we collected the PTMs information including serine/threonine phosphorylation, tyrosine
phosphorylation, acetylation and glycosylation from three major breast cancer subtypes (Luminal
A and B, Her2 positive, Triple-negative) by using serial PTMs enrichment in extracellular vesicles
approach. We compared the profile of each PTMs in each subtype and concluded a panel of
potential PTMs markers for each subtype. In sum, the EV PTMs approach has demonstrated the
feasibility of using different PTMs to distinguish different subtypes in breast cancer, and with the
great potential of applying to other type of cancers.

3.3

Experimental procedure

3.3.1

Plasma sample

The Iowa University Institutional Review Board approved the use of human plasma samples.
In the global PTM-ome experiment, blood samples were collected from 20 healthy females
obtained through Susan G. Komen Tissue Bank and from 20 of each subtypes breast cancer
patients that obtained through the University of Iowa biobank. Plasma samples were collected by
standard protocol, in brief, plasma sample processing was initiated within 30 min of blood draw
to an ethylenediaminetetraacetic acid (EDTA) containing tube. Samples were spun for 30 min at
3500 rpm to remove all cell debris and platelets.
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3.3.2

Extracellular vesicles isolation

The EVs isolation and digestion were performed according to the reported protocol (18). A
total of 5 ml pooled plasma samples were collected from both healthy individuals and patients
diagnosed with breast cancer for the global PTMs experiment as technical replicates. Plasma
samples were centrifuged at 20,000 xg at 4 oC for 1hr. Pellets were washed with cold PBS and
centrifuged again at 20,000 xg at 4 oC for 1 hr, the pellets were microvesicles. Supernatant of the
first centrifugation was further centrifuged at 100,000 xg at 4 oC for 1hr. Pellets were washed with
cold PBS and centrifuged at 100,000 xg for 1hr again. The pellets from ultra-high speed
centrifugations were exosome. Two separate isolated EVs were combined during sample lysis.

3.3.3

Protein digestion

The digestion was performed with phase transfer surfactant aided (PTS) digestion (19).
Extracellular vesicles were solubilized in lysis buffer containing 12mM sodium deoxycholate
(SDC), 12mM sodium lauroyl sarcosinate (SLS) and phosphatase inhibitor cocktail (SigmaAldrich, St. Louis, MO) in 100mM Tris-HCl, pH8.5. Proteins were reduced and alkylated with 10
mM tris-(2-carboxyethyl)phosphine (TCEP) and 40 mM chloroacetamide (CAA) at 95 °C for 5
min. Alkylated proteins were diluted to 5 fold by 50mM triethylammonium bicarbonate (TEAB)
and digested with Lys-C (Wako, Japan) in a 1:100 (w/w) enzyme-to-protein ratio for 3 hr at 37
°C. Trypsin was added to a final 1:50 (w/w) enzyme-to-protein ratio for overnight digestion. The
digested peptides were acidified with trifluoroacetic acid (TFA) to final concentration of 0.5%
TFA, and 250ul of Ethyl acetate was added to 250ul digested solution. The mixture was shaken
for 2 min, then centrifuged at 13,200 rpm for 2 min to obtain aqueous and organic phases. The
aqueous phase was collected and desalted using a 100 mg of Sep-pak C18 column (Waters,
Milford, MA).

3.3.4

Tyrosine phosphopeptides enrichment

Desalted peptides were resuspended in 50mM Tris-HCl pH 7.5, The samples were added with
20uL PT66 beads (Sigma-Aldrich, St. Louis, MO) and incubated with rotation overnight at 4oC.
The PT66 beads were washed sequentially with Lysis buffer (50mM Tris-HCl, 50mM NaCl,
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1%NP40 pH7.5) and water, three times per solution for 10 mins rotation to wash off non-specific
binding. Tyrosine phosphopeptides were sequential eluted twice by 0.1%TFA and once with
0.1%TFA/50%ACN . The eluent was dried under vacuum and then subjected to polymac
enrichment.

3.3.5

Lysine acetylation peptides enrichment

Immunoaffinity enrichment of lysine acetylated peptides from EVs was performed using the
PTMScan protocol as described previously with some modification. In brief, 20ul of lysine
acetylation antibody conjugated beads were washed extensively with PBS. The Flow-through
from tyrosine phosphopeptides were mixed with lysine acetylation antibody beads and incubated
for 2hr at 4oC. The beads were washed twice with IAP buffer (50 mM MOPS, pH 7.2, 10 mM
sodium phosphate, 50 mM NaCl) and three times with water. Peptides were eluted from beads
with 0.15% TFA (sequential elutions of 55 µl followed by 50 µl, 10 min each elution at room
temperature). Eluted peptides were desalted by SDB-XC stage tip and eluted with 40% acetonitrile
in 0.1% TFA. Eluted peptides were dried under vacuum. The flow-through were desalted by SDBXC stage tip and dried under vacuum.

3.3.6

Polymac phosphopeptides enrichment

Peptides were resuspended in 200 µL of loading buffer containing 1% trifluroacetic acid, and
80% acetonitrile and incubated with PolyMAC-Ti silica beads (Tymora Analytical, IN)(20) for
15 min. The beads were loaded into the tip with frit to remove the flow-through. The beads were
washed twice with 200 µL washing buffer containinf 100uM Glycolic acid, 1% TFA, and 50%
ACN and once with 80% ACN, using centrifuge at 100 rcf. The phosphopeptides were then eluted
from the beads by twice with 50 µL of 400 mM ammonium hydroxide, 50%ACN, using centrifuge
at 100 rcf. The eluates were collected and dried under vacuum. The flow-through were dried for
glycopeptides enrichment
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3.3.7

Glycopeptides enrichment

The glycopeptide enrichment was performed according to the reported protocol (21). Desalted
peptides were oxidized with 10 mM sodium periodate in 50% ACN, 0.1% TFA at room
temperature with shaking in the dark for 30 minutes. Excess sodium periodate was quenched by
using 50 mM sodium sulfite for 15 minutes at room temperature with shaking in the dark. The
samples were mixed with 50 µL/100 µL hydrazide magnetic beads for individual and pooled
samples respectively, and incubated with vigorous shaking at room temperature overnight for the
coupling reaction. Magnetic beads were washed sequentially with 400 µL/800 µL of 50% ACN,
0.1% TFA and 1.5 M NaCl for individual and pooled samples respectively, three times per solution
for 1 minute per wash for the removal of non-coupled peptides. Beads were rinsed once with 100
µL/200 µL of 1x GlycoBuffer 2 (NEB) for individual and pooled samples respectively, and
incubated with 3 µL/4 µL of PNGase F (NEB) in 100 µL/200 µL for individual and pooled samples
respectively. N-glycans were cleaved by PNGase F. After desalting, the released former Nglycopeptides were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

3.3.8

LC-MS/MS

The PTMs peptides were dissolved in 4 µL of 0.3% formic acid (FA) with 3% ACN and
injected into an Easy-nLC 1200 (Thermo Fisher Scientific). Peptides were separated on a 45 cm
in-house packed column (360 µm OD × 75 µm ID) containing C18 resin (2.2 µm, 100Å, Michrom
Bioresources) with a 30 cm column heater (Analytical Sales and Services) set to 50 °C. The mobile
phase buffer consisted of 0.1% FA in ultra-pure water (buffer A) with an eluting buffer of 0.1%
FA in 80% ACN (buffer B) run over either with a 45 min or 60 min linear gradient of 5%-25%
buffer B at flow rate of 300 nL/min. The Easy-nLC 1200 was coupled online with a Thermo
Scientific™ Orbitrap Fusion™ Tribrid™ mass spectrometer. The mass spectrometer was operated
in the data-dependent mode in where the 10 most intense ions were subjected to High-energy
collisional dissociation (HCD) fragmentation (normalized collision energy (NCE) 30%, AGC 3e4,
max injection time 100 ms) for each full MS scan (from m/z 350-1500 with a resolution of 120,000
at m/z 200).
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3.3.9

Data Processing

The raw files were searched directly UniprotKB database version Aug2017 with no redundant
entries using MaxQuant software (version 1.5.6.1) (22) with the Andromeda search engine. Initial
precursor mass tolerance was set to 20 p.p.m. and the final tolerance was set to 6 p.p.m., and ITMS
MS/MS tolerance was set at 0.6 Da. Search criteria included a static carbamidomethylation of
cysteines (+57.0214 Da) and variable modifications of (1) oxidation (+15.9949 Da) on methionine
residues, (2) acetylation (+42.011 Da) at N-terminus of protein, and (3) phosphorylation(+79.996
Da) on serine, threonine or tyrosine residues for phosphorylation, acetylation (+42.011 Da) on
Lysine residue for acetylation and deamidation (+0.984Da) on asparagine residues for
glycosylation were searched. Search was performed with Trypsin/P digestion and allowed a
maximum of two missed cleavages on the peptides analyzed from the sequence database. The false
discovery rates of proteins, peptides and PTMs sites were set at 0.01. The minimum peptide length
was six amino acids, and a minimum Andromeda score was set at 40 for modified peptides. The
glycosylation sites were selected based on the matching to the N-X-S/T (X not Pro) motif. A site
localization probability of 0.75 was used as the cut-off for localization of glycosylation sites. All
the peptide spectral matches and MS/MS spectra can be viewed through MaxQuant viewer.

3.3.10 Quantitative Data Analysis
All data was analyzed using the Perseus software (version 1.5.4.1) (23). For quantification of
both proteomic and PTM-omic datasets, the intensities of proteins and PTMs sites were derived
from MaxQuant, and the missing values of intensities were replaced by normal distribution with
a downshift of 1.8 standard deviations and a width of 0.3 standard deviations. The significantly
increased PTMs sites or proteins in patient samples were identified by a ANOVA multi-test with
a permutation-based FDR cut-off 0.05 for all of data sets. For heatmap, the changed sites or
proteins were used, the imputed data set was normalized by z-score within each dataset.

59
3.4

Result

3.4.1

Identification of 11824, 192, 1259 and 805 unique pS/T, pY phosphorylation, Nglycosylation and acetylation peptides from plasma-derived extracellular vesicles

The workflow of integrating proteomics analysis of PTMs by serial enrichment is illustrated
in Figure 3.1. EVs were isolated from human plasma through two steps ultra-high-speed
centrifugation. For the initial screen, the plasma samples were collected and pooled from healthy
individuals (n=20), patients diagnosed with Luminal A or B (n=20), Her 2+ (n=20) and Triple
negative (n=20). After digest of EVs proteins, the desalted peptides were firstly used for tyrosine
phosphorylated peptides enrichment by using PT66 antibody. The flow-through of first enrichment
directly used for the second step which is acetylation enrichment. Then the flow-through of second
enrichment was used for serine, threonine phosphorylated peptides enrichment by Polymac.
Finally, the flow-through from Polymac was used for glycopeptides entichment. All of the PTMs
peptides were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) on a
high-speed and high-resolution mass spectrometer with technical replicates. Label-free
quantitation was performed to determine the differential PTMs proteins in the plasma of control
and three subtypes of breast cancer patient samples. The Strategy allowed us to identify 12016
phosphopeptides including 192 tyrosine phosphorylation, 805 acetylpeptides and 1259
glycopeptides, representing 1699, 453 and 495 proteins. Gene ontology analysis shows that
different PTMs proteins are distinctively from certain cellular location (Figure 3.2). All of PTMs
proteins are significantly enriched from membrane and organelle, phosphoproteins and
glycoproteins are distinctively from plasma membrane, acetylproteins and glycoproteins are
distinctively from extracellular region, phosphoproteins and acetylproteins are distinctively from
cytoplasm. As shown in Figure 3.3A, few protein overlap between each PTMs, and around 40%
of each PTMs proteins are uniquely identified in their own run, indicating the enrichment of PTMome rescued the low-abundance proteins that usually escaping from shut-gun proteomics (Figure
3.3B).
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3.4.2

Cancer specific PTMs peptides in EVs for different subtypes

Label-free quantitation of all PTMs peptides was performed to identify the list of PTMs
proteins changing in three subtypes of breast cancer. We quantified 6281, 62, 393 and 1127 unique
class1 phosphorylation, tyrosine phosphorylation, acetylation and glycosylation sites respectively.
By using ANOVA multi-test, we found that 94 phosphorylation sites have been identified
significantly increased in all subtypes, 20 phosphosites specifically increased in luminal A/B, 67
phosphosites increased in only TN and 31 phosphosites increased in Her2+ (Figure 3.4A). In
addition, as shown in Figure 3.5A, we identified 13 tyrosine phosphorylation sites with
significantly increase in all subtypes versus healthy control, 2 sites in luminal A or B and 3 sites
in TN. For acetylation, 25 acetylsites have been identified with significantly increase in all
subtypes, 24 sites increased in luminal A/B and 2 sites in TN (Figure 3.6A). For glycosylation, we
identified 72 glycosites with a significant increase of abundance in all subtypes, 66, 36 and 14
glycosites increased in Luminal A/B, TN and Her2+, respectively (Figure 3.7A). The difference
in all of PTMs sites may be a result of changes in protein expression or changes of glycosylation
on specific sites. To distinguish these factors, we also performed label-free quantitation of total
EV proteomes. We quantified 2190 proteins, 93% of changed proteins are non-subtype specific.
(Figure 3.8) Among all of changed proteins, less than 40% of the changed PTMs proteins were
also changed in total protein level, indicating the rest of 60% changed PTMs proteins were either
changed due to the modification rather than protein level or cannot be identified due to the low
abundancy (Figure 3.3B).
To evaluate whether PTMs-ome can distinct different subtypes from healthy control, we
applied principle component analysis (PCA) to show that phosphorylation, acetylation not only
distinguish breast cancer from control, but also well-separate different subtypes (Figure 3.4, 3.5,
3.6B). Besides glycosylation can separate breast cancer from healthy control, also indicates that
aggressive breast cancers and Luminal A/B have distinct glycoproteomics profiles (Figure 3.7B).
To better understand the biological roles of differential PTMs events, we examined all PTMs
proteins specific to patients with cancer, using STRING to identify enriched gene ontology
categories and signaling networks. It is interested to reveal that ErbB signaling is significantly
enriched in phosphorylation (Fig. 3.9), which is consisted with previous studies linking ErbB
family signaling to cancer progression in breast cancer. We also found that several metabolic
pathways in acetylation (Fig 3.10) and two major networks including cell adhesion and phagosome
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are in glycosylation for all subtypes (Fig 3.11), persisting previous studies that acetylation links to
controlling cancer cell metabolism (14) and glycosylation plays roles in EVs uptake and cell
adhesion (24).

3.5

Discussion
The traditional classification of breast cancer using ER, PR and Her 2 has been frequently

challenged by samples with exceptional clinical associations, thus determining the characteristics
of four major subtypes has gaining attention. A lot of potential biomarkers such as AR, KI67,
CK, BCL2 and TP53.etc are popular studied. However, very rare of them are used as liquid
biopsy markers. The main issue is that the abundance of tumor leakage proteins is too low to be
detected in blood, so tumor biopsy is still needed for diagnosis of breast cancer and its subtypes.
In this study, we proposed the feasibility of using different PTMs proteins in extracellular
vesicles as different breast cancer subtypes markers. In the first screening result, we clearly see
the different PTMs-omics patterns between each subtype while the patterns look similar in their
global proteomics, indicating that the PTMs can better present the molecular difference between
subtypes. By looking at different PTMs, we are able to inspect the potential roles of PTMs
proteins in EVs-derived cancer metastasis. For example, phosphorylation in molecular signaling,
glycosylation in EVs uptake and acetylation in metabolize. It is interesting that Principle
component analysis shows that glycosylation can well separates aggressive breast cancer from
non-aggressive breast cancer and control, implying the level of metastasis may be altered by the
protein glycosylation level in EVs. We also found that despite the fact that ErbB signaling
commonly increased in all subtypes, nuclear factor of activated T-cells, cytoplasmic 2
(NFATC2) involving in Wnt signaling are significantly higher only in TN, which consists with
previous report that Wnt signaling in TN is associated with cancer metastasis (25).

3.6

Data Access
The raw data, MS identification lists, and quantitation tables for all proteomic analyses have

been

deposited

to

the

ProteomeXchange

(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository.

Consortium
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Figure 3.1 The workflow of serial PTMs-omics in extracellular vesicles for biomarker discovery.
The EVs were isolated from plasma by two step ultra-high speed centrifugation. The serial PTMs enrichments were performed by the
order of 1) Tyrosine phosphorylation 2) Lysine acetylation 3) Serine/Theronine phosphorylation 4) N-Glycosylation after PTS
digestion. Finally, the label-free quantitation was performed.
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Figure 3.2 The cellular component analysis of identified PTMs proteins in plasma EVs.

66

67

Figure 3.3 The comparison of identification and quantitation result between three modifications and total proteome.
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Figure 3.4 The quantitative phosphoproteomics analysis for three breast cancer subtypes.
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Figure 3.5 The quantitative tyrosine phosphoproteomics analysis for three breast cancer subtypes.
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Figure 3.6 The quantitative acetylproteomics analysis for three breast cancer subtypes.
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Figure 3.7 The quantitative glycoproteomics analysis for three breast cancer subtypes.
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Figure 3.8 The quantitative proteomics analysis for three breast cancer subtypes.
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Figure 3.9 The common enriched networking in phosphoproteomics for Luminal A/ B , Her 2 positive and triple negative.
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Figure 3.10 The common enriched networking in acetylproteomics for Luminal A/ B , Her 2 positive and triple negative.
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Figure 3.11 The common enriched networking in glycoproteomics for Luminal A/ B , Her 2 positive and triple negative.
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